ライフサイエンスコーパス: pain relief

1 resulted in clinically useful therapies for pain relief.

2 newborn infants should not be interpreted as pain relief.

3 edicines is intrinsic to achieving effective pain relief.

4 ers to mediate completely different types of pain relief.

5 bitors such as celecoxib are widely used for pain relief.

6 1) is suggested as a therapeutic approach to pain relief.

7 ion while offering a novel, simple method of pain relief.

8 t, such as harnessing endogenous opioids for pain relief.

9 e in their use in children for postoperative pain relief.

10 cking neurotransmission, producing transient pain relief.

11 for chronic low back pain) are effective for pain relief.

12 k pain and may be efficacious for short-term pain relief.

13 pentin (for radiculopathy) are effective for pain relief.

14 resulting in attenuation of opioid-mediated pain relief.

15 hospital admissions, and providing prolonged pain relief.

16 satisfaction with the improved postoperative pain relief.

17 y induced pain can be conditioned to predict pain relief.

18 how humans learn to generate expectations of pain relief.

19 ia, the presence of which was a criterion of pain relief.

20 s were pharmacokinetics, tumor response, and pain relief.

21 e them attractive candidates for therapeutic pain relief.

22 to be treated primarily with analgesics for pain relief.

23 linesterase inhibitors can produce effective pain relief.

24 ural analgesia provides better postoperative pain relief.

25 ipheral metabotropic glutamate receptors for pain relief.

26 oups; all received opioids for postoperative pain relief.

27 uroma, surgical removal can produce dramatic pain relief.

28 lly provide a novel therapeutic strategy for pain relief.

29 tients obtained significant and long-lasting pain relief.

30 creas have a higher likelihood of successful pain relief.

31 the dosage of naproxen without compromising pain relief.

32 ical muscarinic side effects and provides no pain relief.

33 ogy, in addition to its known involvement in pain relief.

34 quired acute medical interventions for their pain relief.

35 alkaloids from the opium poppy are used for pain relief.

36 bility of analgesics, including opioids, for pain relief.

37 uce anxiety and the need for post-procedural pain relief.

38 gnals conveyed by a treatment procedure into pain relief.

39 and hence may offer a new analgesic tool for pain relief.

40 ache by behavioral assessment of reward from pain relief.

41 mental organisations are improving access to pain relief.

42 its ligand, NGF, are in clinical trials for pain relief.

43 rescued opioid responsiveness toward better pain relief.

44 to identify those most likely to experience pain relief.

45 nce the understanding of the biochemistry of pain relief.

46 point was frequency and duration of complete pain relief.

47 353 patients vs 33 [10%] of 343 [p<0.0001]), pain relief (194 [55%] of 353 vs 95 [28%] of 343 [p<0.00

48 Treatment resulted in clinically meaningful pain relief (57% of patients) and reduction or discontin

49 e is an effect supporting meditation-related pain relief above and beyond the effects of placebo.

50 Specifically, mindfulness meditation-induced pain relief activated higher-order brain regions, includ

51 th 32P-orthophosphate, and the similarity in pain relief afforded by 32P-orthophosphate and 89Sr-chlo

52 Forty-three (91%) patients reported pain relief after injections.

53 ortantly, compound 2 produced dose-dependent pain relief after oral administration in CCI rats (ED(50

54 ndependent factor associated with successful pain relief after pancreatic resection.

55 nt was altered in three (37%) as a result of pain relief after the injections.

56 teen of these 21 patients achieved long-term pain relief after their second procedure.

57 are an analgesic option that offer improved pain relief among other benefits.

58 sitive neurons and diminish cooling-mediated pain relief (analgesia).

59 5 months, all patients indicated significant pain relief and 76% were pain free.

60 l steroids (75%) reported 50% or greater leg pain relief and a positive global perceived effect at 1

61 he site of injury, with the hope of enhanced pain relief and a reduction in the side effects associat

62 ients compared the postoperative periodontal pain relief and adverse effects associated with a pretre

63 Clinical outcomes, including pain relief and change in pain medication requirements,

64 dose of diclofenac can provide satisfactory pain relief and decrease substantially the rate of progr

65 are equally effective in providing long-term pain relief and decreasing disease-specific hospital-bas

66 that mindfulness meditation produces greater pain relief and employs distinct neural mechanisms than

67 and heroin, mediating their effects in both pain relief and euphoria.

68 This strategy has prolonged pain relief and facilitated major operations on an outpa

69 s differentially encodes values for expected pain relief and for expected monetary reward.

70 by nonsurgical treatment resulted in greater pain relief and functional improvement after 12 months t

71 ispanic patients in particular reported less pain relief and had less adequate analgesia.

72 or exercise therapy in providing short-term pain relief and improved physical function in patients w

73 islet autotransplantation provides sustained pain relief and improved quality of life.

74 gs indicate that tanezumab provides superior pain relief and improvement in physical function and pat

75 This operation produces durable pain relief and improvement in QOL parameters.

76 nd Frey procedure provide good and permanent pain relief and improvement of the quality of life in lo

77 patients with chronic pancreatitis provides pain relief and improves quality of life, but the effect

78 ternative care delivery system could improve pain relief and reduce unnecessary hospital admissions f

79 low mortality and a good outcome in terms of pain relief and return to work in approximately 60% of p

80 Twelve of 20 patients reported excellent pain relief and returned to work in 3 to 8 weeks.

81 response to treatment (child's assessment of pain relief and sense of improvement).

82 , six patients continued to gain significant pain relief and used the stimulator as the sole treatmen

83 rity of surgery vs endotherapy for long term pain relief and weight gain in painful chronic pancreati

84 ions previously implicated in expectancy for pain-relief and increased attention during treatment of

85 ients receiving ziconotide achieved complete pain relief, and 50.0% of patients receiving ziconotide

86 ch subject, were used to model patient mood, pain relief, and pain intensity scores at three times af

87 s simple, does not require surgery, provides pain relief, and significantly improves cartilage qualit

88 require hospitalization or surgery, provides pain relief, and significantly improves cartilage qualit

89 s simple, does not require surgery, provides pain relief, and significantly improves disc quality.

90 type of multipotent stromal cells, produces pain relief (antihyperalgesia) that lasts for months.

91 tanding how the receptor systems involved in pain relief are altered during acute or chronic pain, an

92 eatitis suggests that the best predictors of pain relief are an intermittent pattern of pain and the

93 that cognitive factors (e.g., expectation of pain relief) are capable of modulating physical and emot

94 We used number needed to treat (NNT) for 50% pain relief as a primary measure and assessed publicatio

95 seems to provide improvement in function and pain relief as an adjunctive therapy for osteoarthritis

96 n the middle- and high-dose cohorts reported pain relief as assessed by NRS and SF-MPQ.

97 nd physician evaluations were used to assess pain relief, as was concurrent change in opioid analgesi

98 or placebo were observed in all trials, with pain relief at 2 hours ranging from 53% to 57.5%.

99 ents in the morphine group failed to achieve pain relief at any time after the dose compared with tho

100 ined DH staff delivered prompt titration for pain relief based on each patient's analgesic history an

101 Can pain relief be provided while reducing negative conseque

102 ties, results in excellent to fair long-term pain relief, but approximately 10% of patients do not re

103 , topical NSAIDs are associated with greater pain relief, but are not associated with an increase in

104 drainage procedures often provide transient pain relief, but long-term recurrence is common due to t

105 It can provide pain relief by an opioid-independent mechanism.

106 exploitation of a novel mechanism providing pain relief by CB(1) inverse agonists.

107 portion of patients without heartburn by D7, pain relief by D7, and reduction in pain intensity by D7

108 CCK(2) receptor antagonists potentiate pain relief by MOP receptor agonists.

109 The duration of this pain relief can range from minutes to an indefinite peri

110 e anti-inflammatory properties of aspirin in pain-relief, cardio-protection, and chemoprevention are

111 rgical drainage provides sustained, superior pain relief compared with endoscopic treatment in patien

112 eceive ketorolac (Toradol) for postoperative pain relief compared with other analgesic agents.

113 02) and pathologic fracture (P = .01), while pain relief correlated with pathologic fracture (P = .03

114 s compared with prednisone alone in terms of pain relief, delayed pain progression, and prevention of

115 ine patients (45%) and partial in six (30%); pain relief did not occur in five patients (25%).

116 he results demonstrate that meditation-based pain relief does not require endogenous opioids.

117 portion of patients who met the criteria for pain relief during the entire evaluation period was not

118 r blockade make them an excellent choice for pain relief during the first stage of labor.

119 patients experiencing clinically significant pain relief), except in the case of tricyclic antidepres

120 l osteolytic metastases provides significant pain relief for cancer patients who have failed standard

121 remains the most effective, safe approach to pain relief for labor, and demand for its use continues

122 of a proposed framework to improve access to pain relief for patients with cancer across the region.

123 f radiofrequency ablation (RFA) in providing pain relief for patients with refractory pain secondary

124 oid injections may provide modest short-term pain relief for some adults with lumbosacral radiculopat

125 with the promise of extensive postoperative pain relief for the ambulatory surgery patient.

126 that have the potential to provide improved pain relief for those many patients whose needs remain p

127 devices have raised the hope of opioid-free pain relief for virtually the entire duration of postsur

128 Postoperative pain relief (freedom from narcotic analgesics) was achie

129 ss than half of patients report satisfactory pain relief from current treatments.

130 ve neuropathic pain in humans who do not get pain relief from opioids.

131 ever, many patients fail to achieve adequate pain relief from these highly brain-penetrant drugs beca

132 sceral pain in chronic pancreatitis predicts pain relief from various treatments, but nonvisceral pai

133 n combination with alcohol ablation provided pain relief from visceral tumors in most patients with i

134 s Survey was used to assess expectations for pain relief, functional improvement, and psychological w

135 Outcomes were pain relief, functional improvement, and radiographic no

136 that experience 50% or greater self-reported pain relief, have stalled.

137 ys of supportive care are airway monitoring, pain relief, hydration, and control of nausea.

138 paired with saphenous nerve block to elicit pain relief (i.e., conditioned place preference, CPP), r

139 y was by far more likely to provide complete pain relief if administered before rather than after the

140 lity contained five subthemes; experience of pain relief, improvements in physical activity, relaxati

141 Celiac plexus block provides short-term pain relief in a subset of patients.

142 uscle relaxants are effective for short-term pain relief in acute low back pain but caused sedation.

143 studies have revealed that HBO2 can produce pain relief in animal models of chronic pain as well.

144 tter survival and symptom control (including pain relief in bone metastases) than those treated with

145 elevating EETs is a novel path to accomplish pain relief in both inflammatory and neuropathic pain st

146 ree-step analgesic ladder leads to effective pain relief in hemodialysis patients.

147 bic) versus a non exercise control group for pain relief in hip OA.

148 ncreased advocacy for the use of opioids for pain relief in infants.

149 Repeat doses are effective in providing pain relief in many patients.

150 Few options are available for pain relief in patients with bone metastases who fail st

151 kle-arthroplasty designs provide substantial pain relief in patients with end-stage ankle osteoarthri

152 thesized that tDCS treatment would result in pain relief in patients with fibromyalgia.

153 ent a novel therapeutic strategy for chronic pain relief in patients with LDH.

154 Although NCPB improves pain relief in patients with pancreatic cancer vs optimi

155 ion of NGX-4010 provided rapid and sustained pain relief in patients with postherpetic neuralgia.

156 patients, triptan therapy provides complete pain relief in some attacks but not in others.

157 It can provide excellent short-term pain relief in some patients, but reliable predictors of

158 The percentage of patients reporting pain relief in the first and second hours after drug adm

159 drugs) analgesic drugs can markedly enhance pain relief in the perioperative period.

160 n significantly impairs HRQOL, and effective pain relief in these patients significantly increases HR

161 Predictors of surgical pain relief include onset of symptoms less than 3 years

162 equally effective in facilitating long-term pain relief, increased activity level, and decreased ana

163 se results implicate opioid receptors in the pain relief induced by HBO2.

164 Systemic sumatriptan did not alter pain relief-induced CPP in rats with incisional injury.

165 Patients tell us that improved pain relief is a principal concern.

166 However, their effectiveness in pain relief is also highly debated and some adverse side

167 hich can be limited to the location at which pain relief is expected.

168 king pain intensity level as an indicator of pain relief is insufficient and can lead to misinterpret

169 Access to essential drugs for pain relief is limited by legal and regulatory restricti

170 irst to demonstrate that mindfulness-related pain relief is mechanistically distinct from placebo ana

171 asive and non-invasive brain stimulation for pain relief is not new.

172 must understand why development of drugs for pain relief is so challenging.

173 In the arena of chronic pancreatitis, pain relief is still the most common reason for surgical

174 Immediate postprocedural pain relief is the best predictor of midterm clinical ou

175 e and, in normal subjects, predicted reward (pain relief) magnitude at stimulus offset.

176 nergic inhibition is an important endogenous pain-relief mechanism which can be activated by local gl

177 c awareness, and gaps in access to essential pain-relief medicines.

178 h that the amount of drug required to elicit pain relief must be increased to compensate for diminish

179 In terms of the extent and time course of pain relief, NGF blockade also reduced pain 40% to 70%,

180 ain, pain-related functional impairment, and pain relief obtained by taking analgesic drugs.

181 Immediate pain relief of 100% was achieved in all patients.

182 , in a general population admitted for chest pain, relief of pain after nitroglycerin treatment does

183 targeting central sites may be required for pain relief once BTP has been initiated.

184 ome events gathered during annual follow-up: pain relief, onset of diabetes, body weight maintenance,

185 ding their perceived importance of providing pain relief or avoiding adverse drug effects may have im

186 percentage or larger volume leads to better pain relief or decreased pain (P > .05).

187 done was not associated with superior cancer pain relief or fewer adverse effects compared with other

188 five co-primary endpoints were pain freedom, pain relief, or absence of photophobia, phonophobia, or

189 (MR)-guided RFA and/or alcohol ablation for pain relief over a 2-year period were retrospectively id

190 Higher preference to provide pain relief (over avoid analgesic risk) lessened the lik

191 y artery disease, 41% (113 of 275) had chest pain relief (P > 0.2).

192 e capsaicin cream arm had substantially more pain relief (P = .01) after the first 8 weeks, with an a

193 he unipediculate procedure achieved adequate pain relief (P =.65) with mean decreases in pain severit

194 ronic pancreatitis is beneficial in terms of pain relief, pancreatic function and quality of life, co

195 t phase, pain modulation and expectations of pain relief persisted to a larger degree in the treatmen

196 -the-clock medication.) Pain intensity (PI), pain relief (PR), and global satisfaction scores were re

197 e, parents completed surveys assessing their pain relief preference (i.e., their rated importance of

198 t is palliative, with the principle goals of pain relief, preservation of neurologic function, and im

199 er, a newly introduced bill in Congress, the Pain Relief Promotion Act of 1999 (PRPA), could dramatic

200 the effect of epidural analgesia and PCA on pain relief, pulmonary function, cathechol release, and

201 Outcome measures include functional (pain relief, quality of life [QoL]), medical (endo- and

202 f pain as recorded in a diary, the degree of pain relief, quality of life, psychological and cognitiv

203 Acute therapy includes complete pain relief, rehydration, and encouragement of diuresis.

204 preference (i.e., their rated importance of pain relief relative to adverse drug event avoidance), p

205 agement by harnessing endogenous opioids for pain relief.SIGNIFICANCE STATEMENT The current prescript

206 Pain relief starts 1-4 weeks after the initiation of tre

207 tly less analgesic medication but had better pain relief than group 1 patients.

208 TDF provided significantly better pain relief than placebo, as demonstrated by the primary

209 atory drugs (NSAIDs) associated with greater pain relief than placebo, other drugs, and nondrug treat

210 ative in polarity, suggesting that the acute pain relieves the ongoing back pain.

211 nterest has focused on TRPV1 as a target for pain relief, the chronic blockade of this pain receptor

212 ight have been used for complication-related pain relief, the odds of complications associated with k

213 Phenomena such as placebo analgesia or pain relief through distraction highlight the powerful i

214 isingly few patients, and provide equivalent pain relief to 65% of selected patients.

215 suggests that hypnosis can provide temporary pain relief to the majority of individuals with chronic

216 s, or coxibs, designed to provide comparable pain relief to traditional nonsteroidal anti-inflammator

217 ents for neuropathic pain deliver inadequate pain relief, unacceptable side effects, or both.

218 The methods of pain relief used or discussed include nonpharmacologic t

219 it neuroprotection and sustained neuropathic pain relief via TGF-beta1 secretion.

220 The mean duration of pain relief was 11.8 months after RFN, with a maximum av

221 Long-term pain relief was achieved in 90%, and pseudocyst recurren

222 Pain relief was analysed post hoc.

223 Immediate neuropathic pain relief was assessed by visual analogue scale (VAS)

224 As secondary measures, efficacy of pain relief was assessed using a numeric rating scale (N

225 Mindfulness-meditation-related pain relief was associated with greater activation in br

226 Complete or partial pain relief was attained in 60% and 70% of patients afte

227 Pain relief was categorized as complete, partial, minima

228 At study endpoint, pain relief was comparable among all lumiracoxib dosages

229 At 1-6-week follow-up, pain relief was complete in nine patients (45%) and part

230 Chest pain relief was defined as a decrease of at least 50% in

231 Pain relief was excellent in 7% and good in 38% of child

232 Pain relief was moderate to complete in 52.9% of patient

233 Pain relief was more common in patients with diabetes or

234 mg above the naproxen daily dosage at which pain relief was no longer adequate.

235 In 100% cases pain relief was observed immediately after the procedure

236 Pain relief was observed in 62% to 72% of those who rece

237 Pain relief was observed within 1 week of administration

238 Persistence of pain relief was seen through week 16 in 43% of patients

239 Pain relief was similar in both groups.

240 On D7, overall quality of pain relief was slightly in favour of omeprazole (p = 0.

241 For effective interventions, pain relief was small to moderate and generally short-te

242 Decreases in prostate-specific antigen and pain relief were noted in a patient subset.

243 alf, thereby achieving prolonged neuropathic pain relief while doubling the margin of safety against

244 Pain relief with 153Sm-EDTMP was 75%: 33.33% complete, 5

245 Pain relief with 177Lu-EDTMP was 80%: 50% complete, 41.6

246 Pain relief with adjunct means of pain modulation should

247 Pain relief with anesthetic injection helped confirm the

248 ed pharmaceuticals hold forth the promise of pain relief with improved side-effect profiles over curr

249 re similar in patients with or without chest pain relief with nitroglycerin (P > 0.2).

250 The belief that chest pain relief with nitroglycerin indicates the presence of

251 their chest pain, 35% (49 of 141) had chest pain relief with nitroglycerin.

252 ignificant impediments to achieving adequate pain relief with opioids.

253 Excellent pain relief with regional anesthesia is well demonstrate

254 Radioisotopes are effective in providing pain relief with response rates of between 40% and 95%.

255 Eight subjects had statistically significant pain relief with the electrical stimulator (p < 0.02) an

256 he patients were titrated to relief; 90% had pain relief within 2 to 4 hours.

257 rons, such an approach might offer effective pain relief without a significant side-effect liability.

258 ely lead to therapeutics designed to provide pain relief without the adverse side effects normally as

259 ng ankle-brachial index, toe-brachial index, pain relief, wound healing, or major amputation.